Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 159632, 5 pages
http://dx.doi.org/10.1155/2014/159632
Research Article

Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia

1Hematology Section of the First Department of Propedeutic Internal Medicine, Laikon University Hospital, Agiou Thoma 17, 11527 Athens, Greece
2Hematology Clinic of Athens’ Medical Center, Andersen 1, Psychiko, 11525 Athens, Greece

Received 17 April 2014; Accepted 20 July 2014; Published 6 August 2014

Academic Editor: Kazuyuki Shimizu

Copyright © 2014 Marie-Christine Kyrtsonis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Swerdlow, E. Campo, and N. E. Harris, Eds., WHO Classification of Tumours of Haematipoetic and Lymphoid Tissues, Lyon IARC Press, 2008.
  2. M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Matutes, K. Owusu-Ankomah, R. Morilla et al., “The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL,” Leukemia, vol. 8, no. 10, pp. 1640–1645, 1994. View at Google Scholar · View at Scopus
  4. P. Cramer and M. Hallek, “Prognostic factors in chronic lymphocytic leukemia—what do we need to know?” Nature Reviews Clinical Oncology, vol. 8, no. 1, pp. 38–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. J. Novak, R. J. Bram, N. E. Kay, and D. F. Jelinek, “Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival,” Blood, vol. 100, no. 8, pp. 2973–2979, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. M.-C. Kyrtsonis, K. Sarris, T. Tzenou, and D. Maltezas, “B-lymphocyte stimylator (BLyS) role in chronic lymphocytic leukaemia (CLL), Waldenström’s Macroglobulinaemia (WM) and Multiple Myeloma (MM). Treatment strategies,” Hematology, 2013. View at Google Scholar
  7. A. Craxton, D. Magaletti, E. J. Ryan, and E. A. Clark, “Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF,” Blood, vol. 101, no. 11, pp. 4464–4471, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Melchers, “Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease,” Annals of the Rheumatic Diseases, vol. 62, supplement 2, pp. ii25–ii27, 2003. View at Google Scholar · View at Scopus
  9. F. Mackay and C. Ambrose, “The TNF family members BAFF and APRIL: the growing complexity,” Cytokine and Growth Factor Reviews, vol. 14, no. 3-4, pp. 311–324, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Mackay and J. L. Browning, “BAFF: a fundamental survival factor for B cells,” Nature Reviews Immunology, vol. 2, no. 7, pp. 465–475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Mackay, P. Schneider, P. Rennert, and J. Browning, “BAFF and APRIL: a tutorial on B cell survival,” Annual Review of Immunology, vol. 21, pp. 231–264, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Ferrer, K. Hodgson, E. Montserrat, and C. Moreno, “B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity,” Leukemia and Lymphoma, vol. 50, no. 7, pp. 1075–1082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Planelles, S. Castillo-Gutiérrez, J. P. Medema, A. Morales-Luque, H. Merle-Béral, and M. Hahne, “APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival,” Haematologica, vol. 92, no. 9, pp. 1284–1285, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Molica, G. Digiesi, C. Battaglia et al., “Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia,” European Journal of Haematology, vol. 85, no. 4, pp. 314–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. M. Ansell, A. J. Novak, S. Ziesmer et al., “Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma,” The American Journal of Hematology, vol. 84, no. 2, pp. 71–73, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J.-F. Rossi, J. Moreaux, D. Hose et al., “Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study,” British Journal of Cancer, vol. 101, no. 7, pp. 1051–1058, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. N. S. Raje, R. J. Hohl, E. A. Faber et al., “Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma,” Journal of Clinical Oncology, vol. 29, supplement, abstract 8012, 2011. View at Google Scholar
  18. M. C. Kyrtsonis, K. Sarris, G. Pangalis et al., “Contradictory impact of serum BLyS levels in Chronic Lymphocytic leukemia, Waldestrom's macroglobulinemia and Multiple Myeloma,” EHA, Abstr 741, 2012.
  19. G. Pratt, S. Harding, R. Holder et al., “Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia,” The British Journal of Haematology, vol. 144, no. 2, pp. 217–222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Morabito, R. de Filippi, L. Laurenti et al., “The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia,” Blood, vol. 118, no. 24, pp. 6353–6361, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Sarris, D. Maltezas, E. Koulieris et al., “Prognostic significance of serum free light chains in chronic lymphocytic leukemia,” Advances in Hematology, vol. 2013, Article ID 359071, 7 pages, 2013. View at Publisher · View at Google Scholar